查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1421583

藥物基因組學技術市場、份額、規模、趨勢、行業分析報告：按技術、按治療領域、按地區和細分趨勢，2023-2032

Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球藥物基因組學技術市場預計將達到 141 億美元。

這份研究報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

診斷領域正在經歷一場變革，以適應藥物基因組測試的不斷增加，而藥物基因組測試通常伴隨著新的生物療法的引入。 這些測試具有雙重好處，不僅可以提供具有成本效益的治療選擇，還可以增強藥物開發過程。

與傳統方法相比，採用這些測試的優勢非常顯著。 首先，這些測試可以預測疾病風險，並幫助識別更容易受到某些疾病影響的個體。 其次，這些測試有助於對患者進行分層，使醫療保健提供者能夠根據每位患者的特定遺傳特徵制定治療方案。 這種個人化方法可以帶來更有效的治療和更少的副作用。 最後，藥物基因組學測試可以幫助監測治療反應，以確保治療步入正軌並允許根據需要進行調整。

藥物基因組測試產品在協助醫療保健專業人員為個別患者量身定制和優化治療方案方面發揮著重要作用。 藥物基因組學和治療診斷學領域正在為綜合醫學開闢新的途徑。 此專門類別的分子診斷測試的快速進步將積極增強即時疾病治療評估並改善患者護理。

然而，及時將基於藥物基因組學的測試整合到藥物開發過程中也存在挑戰，這可能會阻礙同時批准。 旨在確定個體和人群對特定治療反應的差異的臨床試驗的有效設計和實施已成為治療診斷成功的重要組成部分。

藥物基因體學技術市場報告重點

  • 由於癌症發生率不斷上升，以及全球對個人化治療、腫瘤分析和診斷產量增加的需求不斷增長，預計腫瘤學將成為預測期內增長最快的領域。
  • 2022 年，PCR 細分市場佔據最大市場份額。 這是因為治療診斷學取得了重大進展，其與高效率和高通量篩選相關的優勢已被最終用戶所採用。
  • 2022 年，北美佔據最大的市場份額。 這是由於主要參與者、發達的行業大大小小的參與者、大量的研究人員以及廣泛的行業學術界網絡的存在。

目錄

第 1 章簡介

第 2 章執行摘要

第 3 章研究方法

第 4 章全球藥物基因體學技術市場洞察

  • 藥物基因體學技術市場 - 產業概況
  • 藥物基因體學技術市場動態
    • 促進因素和機會
      • 提高對個人化醫療保健的認識和採用
      • 技術進步
    • 抑制因素和挑戰
      • 費用和退款
  • PESTLE分析
  • 藥物基因體學技術的產業趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第 5 章全球藥物基因體學技術市場：依技術分類

  • 主要發現
  • 簡介
  • PCR
  • 原位雜交
  • 免疫組織化學
  • 序列
  • 其他

第 6 章全球藥物基因體學技術市場：依治療領域劃分

  • 主要發現
  • 簡介
  • 腫瘤學
  • 神經系統疾病
  • 循環系統疾病
  • 免疫性疾病
  • 傳染病
  • 其他

第 7 章全球藥物基因體學技術市場：按地區

  • 主要發現
  • 簡介
    • 2019-2032 年藥物基因體學技術市場評估，地區
  • 藥物基因體學技術市場 - 北美
    • 北美：藥物基因體學技術市場，依治療領域劃分，2019-2032 年
    • 北美：藥物基因體學技術市場，按技術，2019-2032 年
    • 藥物基因體學技術市場 - 美國
    • 藥物基因體學技術市場 - 加拿大
  • 藥物基因體學技術市場 - 歐洲
    • 歐洲：藥物基因體學技術市場，依治療領域劃分，2019-2032 年
    • 歐洲：藥物基因體學技術市場，按技術，2019-2032 年
    • 藥物基因體學技術市場 - 英國
    • 藥物基因體學技術市場 - 法國
    • 藥物基因體學技術市場 - 德國
    • 藥物基因體學技術市場 - 義大利
    • 藥物基因體學技術市場 - 西班牙
    • 藥物基因體學技術市場 - 荷蘭
    • 藥物基因體學技術市場 - 俄羅斯
  • 藥物基因體學技術市場 - 亞太地區
    • 亞太地區：藥物基因體學技術市場，依治療領域劃分，2019-2032 年
    • 亞太地區：藥物基因體學技術市場，按技術，2019-2032 年
    • 藥物基因體學技術市場 - 中國
    • 藥物基因體學技術市場 - 印度
    • 藥物基因體學技術市場 - 馬來西亞
    • 藥物基因體學技術市場 - 日本
    • 藥物基因組學技術市場 - 印度尼西亞
    • 藥物基因體學技術市場 - 韓國
  • 藥物基因體學技術市場 - 中東和非洲
    • 中東與非洲：藥物基因體學技術市場，依治療領域劃分，2019-2032 年
    • 中東和非洲：藥物基因組學技術市場，按技術，2019-2032 年
    • 藥物基因組學技術市場 - 沙烏地阿拉伯
    • 藥物基因體學技術市場 - 阿拉伯聯合大公國
    • 藥物基因體學技術市場 - 以色列
    • 藥物基因體學技術市場 - 南非
  • 藥物基因體學技術市場 - 拉丁美洲
    • 拉丁美洲：藥物基因體學技術市場，依治療領域劃分，2019-2032 年
    • 拉丁美洲：藥物基因體學技術市場，按技術，2019-2032 年
    • 藥物基因體學技術市場 - 墨西哥
    • 藥物基因體學技術市場 - 巴西
    • 藥物基因體學技術市場 - 阿根廷

第 8 章競爭態勢

  • 擴張與收購分析
    • 擴大
    • 收購
  • 夥伴關係/協作/協議/揭露

第 9 章公司簡介

  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GE HealthCare
  • Illumina, Inc
  • Leica Biosystems Nussloch GmBH
  • MDPI
  • Pfizer Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc
Product Code: PM3906

The global pharmacogenomics technologies market size is expected to reach USD 14.10 billion by 2032, according to a new study by Polaris Market Research.

The report "Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The field of diagnostics is undergoing a transformation as it adapts to the increasing availability of pharmacogenomic tests, often accompanying the introduction of new biological therapies. These tests have the dual benefit of not only providing cost-effective treatment options but also enhancing the drug development process.

The advantages associated with the adoption of these tests over traditional methods are substantial. First, they enable the prediction of disease risks, helping identify individuals who are more susceptible to certain conditions. Second, these tests aid in patient stratification, allowing healthcare providers to tailor treatments to the specific genetic characteristics of each patient. This personalized approach leads to more effective therapies and fewer adverse effects. Finally, pharmacogenomic tests are instrumental in monitoring therapeutic responses, ensuring that treatments are on track and adjustments can be made when necessary.

Pharmacogenomics testing products play a crucial role in assisting healthcare professionals in customizing and optimizing the therapeutic regimens for individual patients. The realms of pharmacogenomics and theranostics are opening new avenues for integrated medicine. The rapid advancements within this specialized category of molecular diagnostic tests are actively enhancing the assessment of real-time disease treatment, leading to improvements in patient care.

Nevertheless, there are challenges related to the timely integration of pharmacogenomic-based testing into drug development processes, which can hinder simultaneous approval. The effective design and execution of clinical trials aimed at identifying individual and population variations in response to a particular therapy have become essential factors for the success of theranostics.

Pharmacogenomics Technologies Market Report Highlights

  • The oncology segment is expected to witness the fastest growth during the forecast period, as there is growing onset of cancer, increasing need for personalized treatment, tumor profiling, rise in diagnosis rate, across the globe.
  • In 2022, PCR segment held the largest market share, as there are significant advancements in theranostics, advantages associated with its higher efficiency and high throughput screening coupled with adoption among end users.
  • In 2022, North America held the largest market share, owing to presence of key players, well developed industry big and small players, huge pool of researchers, and extensive network of industry academia.
  • The key market players include QIAGEN, GE HealthCare, Agilent Technologies, Roche, Foundation Medicine, Thermo Fisher Scientific., Leica Biosystems, and Pfizer.

Polaris Market Research has segmented the pharmacogenomics technologies market report based on technology, therapeutic area, and region:

Pharmacogenomics Technologies, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

  • PCR
  • In-situ Hybridization
  • Immunohistochemistry
  • Sequencing
  • Others

Pharmacogenomics Technologies, Therapeutic Area Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Pharmacogenomics Technologies, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pharmacogenomics Technologies Market Insights

  • 4.1. Pharmacogenomics Technologies Market - Industry Snapshot
  • 4.2. Pharmacogenomics Technologies Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Awareness and Adoption of Personalized Healthcare
      • 4.2.1.2. Advancements in Technology
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Costs and Reimbursement
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Pharmacogenomics Technologies Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pharmacogenomics Technologies Market, by Technology

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pharmacogenomics Technologies, by Technology, 2019-2032 (USD Billion)
  • 5.3. PCR
    • 5.3.1. Global Pharmacogenomics Technologies Market, by PCR, by Region, 2019-2032 (USD Billion)
  • 5.4. In-situ Hybridization
    • 5.4.1. Global Pharmacogenomics Technologies Market, by In-situ Hybridization, by Region, 2019-2032 (USD Billion)
  • 5.5. Immunohistochemistry
    • 5.5.1. Global Pharmacogenomics Technologies Market, by Immunohistochemistry, by Region, 2019-2032 (USD Billion)
  • 5.6. Sequencing
    • 5.6.1. Global Pharmacogenomics Technologies Market, by Sequencing, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Pharmacogenomics Technologies Market, by Therapeutic Area

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 6.3. Oncology
    • 6.3.1. Global Pharmacogenomics Technologies Market, by Oncology, by Region, 2019-2032 (USD Billion)
    • 6.3.2. Lung Cancer
      • 6.3.2.1. Global Pharmacogenomics Technologies Market, by Lung Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.3. Breast Cancer
      • 6.3.3.1. Global Pharmacogenomics Technologies Market, by Breast Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.4. Colorectal Cancer
      • 6.3.4.1. Global Pharmacogenomics Technologies Market, by Colorectal Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.5. Cervical Cancer
      • 6.3.5.1. Global Pharmacogenomics Technologies Market, by Cervical Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.6. Others
      • 6.3.6.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)
  • 6.4. Neurological Disorders
    • 6.4.1. Global Pharmacogenomics Technologies Market, by Neurological Disorders, by Region, 2019-2032 (USD Billion)
  • 6.5. Cardiovascular Disease
    • 6.5.1. Global Pharmacogenomics Technologies Market, by Cardiovascular Disease, by Region, 2019-2032 (USD Billion)
  • 6.6. Immunological Disorders
    • 6.6.1. Global Pharmacogenomics Technologies Market, by Immunological Disorders, by Region, 2019-2032 (USD Billion)
  • 6.7. Infectious Diseases
    • 6.7.1. Global Pharmacogenomics Technologies Market, by Infectious Diseases, by Region, 2019-2032 (USD Billion)
  • 6.8. Others
    • 6.8.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Pharmacogenomics Technologies Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Pharmacogenomics Technologies Market - North America
    • 7.3.1. North America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.3.2. North America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.3.3. Pharmacogenomics Technologies Market - U.S.
      • 7.3.3.1. U.S.: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.3.4. Pharmacogenomics Technologies Market - Canada
      • 7.3.4.1. Canada: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.4. Pharmacogenomics Technologies Market - Europe
    • 7.4.1. Europe: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.3. Pharmacogenomics Technologies Market - UK
      • 7.4.3.1. UK: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.4. Pharmacogenomics Technologies Market - France
      • 7.4.4.1. France: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.5. Pharmacogenomics Technologies Market - Germany
      • 7.4.5.1. Germany: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.6. Pharmacogenomics Technologies Market - Italy
      • 7.4.6.1. Italy: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.7. Pharmacogenomics Technologies Market - Spain
      • 7.4.7.1. Spain: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.8. Pharmacogenomics Technologies Market - Netherlands
      • 7.4.8.1. Netherlands: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.9. Pharmacogenomics Technologies Market - Russia
      • 7.4.9.1. Russia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.5. Pharmacogenomics Technologies Market - Asia Pacific
    • 7.5.1. Asia Pacific: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.3. Pharmacogenomics Technologies Market - China
      • 7.5.3.1. China: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.4. Pharmacogenomics Technologies Market - India
      • 7.5.4.1. India: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.5. Pharmacogenomics Technologies Market - Malaysia
      • 7.5.5.1. Malaysia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.6. Pharmacogenomics Technologies Market - Japan
      • 7.5.6.1. Japan: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.7. Pharmacogenomics Technologies Market - Indonesia
      • 7.5.7.1. Indonesia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.8. Pharmacogenomics Technologies Market - South Korea
      • 7.5.8.1. South Korea: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.6. Pharmacogenomics Technologies Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.3. Pharmacogenomics Technologies Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.4. Pharmacogenomics Technologies Market - UAE
      • 7.6.4.1. UAE: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.5. Pharmacogenomics Technologies Market - Israel
      • 7.6.5.1. Israel: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.6. Pharmacogenomics Technologies Market - South Africa
      • 7.6.6.1. South Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.7. Pharmacogenomics Technologies Market - Latin America
    • 7.7.1. Latin America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.3. Pharmacogenomics Technologies Market - Mexico
      • 7.7.3.1. Mexico: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.4. Pharmacogenomics Technologies Market - Brazil
      • 7.7.4.1. Brazil: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.5. Pharmacogenomics Technologies Market - Argentina
      • 7.7.5.1. Argentina: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Agilent Technologies, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. F. Hoffmann-La Roche Ltd
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Foundation Medicine, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GE HealthCare
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Illumina, Inc
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Leica Biosystems Nussloch GmBH
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. MDPI
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Pfizer Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. QIAGEN
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Thermo Fisher Scientific Inc
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development

List of Tables

  • Table 1 Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 2 Global Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 3 Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 5 North America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 6 U.S.: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 7 U.S.: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 8 Canada: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 9 Canada: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 10 Europe: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 11 Europe: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 12 UK: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 13 UK: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 14 France: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 15 France: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 16 Germany: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 17 Germany: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 18 Italy: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 19 Italy: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 20 Spain: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 21 Spain: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 24 Russia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 25 Russia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 28 China: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 29 China: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 30 India: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 31 India: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 34 Japan: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 35 Japan: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 38 South Korea: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 39 South Korea: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 44 UAE: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 45 UAE: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 46 Israel: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 47 Israel: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 48 South Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 49 South Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 50 Latin America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 51 Latin America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 52 Mexico: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 53 Mexico: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 54 Brazil: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 55 Brazil: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 56 Argentina: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 57 Argentina: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Pharmacogenomics Technologies Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Therapeutic Area
  • Figure 7 Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Technology
  • Figure 9 Global Pharmacogenomics Technologies Market, by Technology, 2022 & 2032 (USD Billion)
  • Figure 10 Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Pharmacogenomics Technologies Market